MCID: PNC008
MIFTS: 36

Pancreatic Endocrine Carcinoma

Categories: Endocrine diseases, Cancer diseases, Neuronal diseases

Aliases & Classifications for Pancreatic Endocrine Carcinoma

MalaCards integrated aliases for Pancreatic Endocrine Carcinoma:

Name: Pancreatic Endocrine Carcinoma 12 14 69
Malignant Neoplasm of Islets of Langerhans 12
Pancreatic Neuroendocrine Carcinoma 12
Carcinoma of Endocrine Pancreas 12
Carcinoma, Islet Cell 42
Islet Cell Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1798
ICD10 33 C25.4
ICD9CM 35 157.4
MeSH 42 D018273
NCIt 47 C3770
UMLS 69 C1328479

Summaries for Pancreatic Endocrine Carcinoma

Disease Ontology : 12 An islet cell tumor that has material basis in epithelial cells.

MalaCards based summary : Pancreatic Endocrine Carcinoma, also known as malignant neoplasm of islets of langerhans, is related to islet cell tumor and pancreatic islet cell tumors. An important gene associated with Pancreatic Endocrine Carcinoma is SSTR2 (Somatostatin Receptor 2), and among its related pathways/superpathways is Neural Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Oxaliplatin and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include pancreas, liver and bone, and related phenotype is behavior/neurological.

Related Diseases for Pancreatic Endocrine Carcinoma

Diseases related to Pancreatic Endocrine Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 68)
id Related Disease Score Top Affiliating Genes
1 islet cell tumor 11.0
2 pancreatic islet cell tumors 11.0
3 oral leukoedema 10.4 SST SSTR2
4 mononeuritis of upper limb and mononeuritis multiplex 10.4 SST SSTR2
5 renal pelvis carcinoma 10.3 SST SSTR2
6 ludwig's angina 10.3 NCAM1 SYP
7 breast apocrine carcinoma in situ 10.3 SST SYP
8 glomus tumor 10.3 NCAM1 SYP
9 cystitis cystica 10.3 NCAM1 SYP
10 pemphigus foliaceus 10.3 SST SYP
11 gallbladder adenocarcinoma 10.3 NCAM1 SYP
12 chondroid chordoma 10.3 NCAM1 SYP
13 anal canal adenocarcinoma 10.3 SSTR2 SYP
14 hypogonadotropic hypogonadism without anosmia, x-linked 10.3 NCAM1 SYP
15 diffuse lipomatosis 10.3 NCAM1 SYP
16 thyroid sarcoma 10.3 NCAM1 SYP
17 sm-ahnmd 10.3 NCAM1 SYP
18 thymus small cell carcinoma 10.3 NCAM1 SYP
19 malignant teratoma 10.3 NCAM1 SYP
20 sudden sensorineural hearing loss 10.3 NCAM1 SYP
21 tabes dorsalis 10.3 SST SYP
22 encephalitozoonosis 10.3 NCAM1 SYP
23 pneumonia 10.3 NCAM1 SYP
24 ethmoid sinus schneiderian papilloma 10.3 NCAM1 SYP
25 pancreatitis 10.3
26 rete ovarii cystadenofibroma 10.3 SST SYP
27 urethra clear cell adenocarcinoma 10.3 NCAM1 SYP
28 pancreatic agenesis 10.2 NCAM1 SYP
29 trachea sarcoma 10.2 NCAM1 SYP
30 migraine with aura 10.2 SST SYP
31 bladder cancer, childhood 10.2 SST SYP
32 carcinoma of unknown primary site, childhood 10.2 SST SYP
33 internal auditory canal lipoma 10.2 NCAM1 SYP
34 early-onset parkinson disease 10.2 SST SYP
35 volkmann contracture 10.2 SST SYP
36 caroli disease 10.2 NCAM1 SYP
37 benign peritoneal mesothelioma 10.2 NCAM1 SYP
38 cavernous hemangioma 10.2 NCAM1 SYP
39 hypogonadism 10.1 NCAM1 SYP
40 olfactory neuroblastoma 10.1 NCAM1 SYP
41 vestibular gland benign neoplasm 10.1 SST SYP
42 persistent hyperplastic primary vitreous 10.1 NCAM1 SYP
43 brachyolmia 10.0 NCAM1 SYP
44 postmenopausal atrophic vaginitis 10.0 NCAM1 SYP
45 psychogenic movement 10.0 SST SSTR5
46 ovarian large-cell neuroendocrine carcinoma 9.9 NCAM1 SYP
47 cowden syndrome 3 9.9 SST SSTR2 SYP
48 seminoma 9.9 SST SSTR2 SYP
49 autoimmune lymphoproliferative syndrome 9.9 SST SSTR2 SYP
50 cystadenoma 9.9 NCAM1 SYP

Graphical network of the top 20 diseases related to Pancreatic Endocrine Carcinoma:



Diseases related to Pancreatic Endocrine Carcinoma

Symptoms & Phenotypes for Pancreatic Endocrine Carcinoma

MGI Mouse Phenotypes related to Pancreatic Endocrine Carcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.02 FOXK1 NCAM1 SST SSTR2 SYP

Drugs & Therapeutics for Pancreatic Endocrine Carcinoma

Drugs for Pancreatic Endocrine Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 105)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 2, Phase 3,Phase 1 61825-94-3 5310940 9887054 43805 6857599
2
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
3
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
4
Levoleucovorin Approved Phase 2, Phase 3,Phase 1 68538-85-2
5
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
6
Somatostatin Approved Phase 2, Phase 3,Phase 1 38916-34-6, 51110-01-1 53481605
7
leucovorin Approved, Nutraceutical Phase 2, Phase 3, Phase 1 58-05-9 143 6006
8
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
9 Pancreatic Polypeptide Investigational Phase 2, Phase 3, Phase 1 59763-91-6
10 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 1
11 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 1
12 Immunosuppressive Agents Phase 2, Phase 3,Phase 1
13 Antimetabolites Phase 2, Phase 3,Phase 1
14 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1
15 Analgesics Phase 3
16 Central Nervous System Depressants Phase 3
17 Adjuvants, Anesthesia Phase 3
18 Narcotics Phase 3
19 Analgesics, Opioid Phase 3
20 Anesthetics Phase 3
21 Hormone Antagonists Phase 2, Phase 3,Phase 1
22 Anesthetics, General Phase 3
23 Anesthetics, Intravenous Phase 3
24 Hormones Phase 2, Phase 3,Phase 1
25 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3,Phase 1
26 Peripheral Nervous System Agents Phase 3
27 Liver Extracts Phase 3,Phase 2,Phase 1
28 Folate Nutraceutical Phase 2, Phase 3
29 Vitamin B9 Nutraceutical Phase 2, Phase 3
30 Cola Nutraceutical Phase 3,Phase 2,Phase 1
31
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
32
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
33
Melphalan Approved Phase 2 148-82-3 4053 460612
34
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 498142 38904
35
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
36
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
37
Octreotide Approved, Investigational Phase 2,Phase 1 83150-76-9 383414 6400441
38
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
39
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
40
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
41
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
42
Streptozocin Approved Phase 2 18883-66-4 29327
43
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
44
Pancrelipase Approved Phase 2 53608-75-6
45
Etoposide Approved Phase 2 33419-42-0 36462
46
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
47
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
48
Lenograstim Approved Phase 2 135968-09-1
49
nivolumab Approved Phase 2 946414-94-4
50
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062

Interventional clinical trials:

(show top 50) (show all 52)

id Name Status NCT ID Phase Drugs
1 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
2 Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors Completed NCT00442533 Phase 2, Phase 3 Indium-111 pentetreotide
3 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
4 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
5 A Study of IMC-A12 in Islet Cell Cancer Completed NCT00781911 Phase 2 depot octreotide
6 Interferon and Octreotide to Treat Zollinger-Ellison Syndrome and Advanced Non-B Islet Cell Cancer Completed NCT00001228 Phase 2 Interferon
7 Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00027638 Phase 2 thalidomide
8 RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma Completed NCT00113360 Phase 2 RAD001;Octreotide Depot
9 Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET) Completed NCT01169649 Phase 2 MK-2206
10 Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy Completed NCT00363051 Phase 2 Everolimus 10 mg;Octreotide Depot
11 Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma Completed NCT00093782 Phase 2 temsirolimus
12 Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors Completed NCT00602082 Phase 2 capecitabine;cisplatin;streptozocin
13 Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00131911 Phase 2 sorafenib tosylate
14 Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00075439 Phase 2 gefitinib
15 Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer Completed NCT00454363 Phase 2 Pazopanib Hydrochloride
16 Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery Completed NCT00416767 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
17 Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases Completed NCT00019786 Phase 2 isolated perfusion;melphalan
18 AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2 AMG 706;octreotide
19 Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer Completed NCT00096083 Phase 2 isolated perfusion;melphalan
20 Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II Recruiting NCT02230176 Phase 2 Sunitinib;177Lu-DOTA0-Tyr3-Octreotate
21 Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery Recruiting NCT02595424 Phase 2 Capecitabine;Carboplatin;Cisplatin;Etoposide;Temozolomide
22 Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery Recruiting NCT02893930 Phase 2 Sapanisertib
23 FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas Recruiting NCT03042780 Phase 2 FOLFIRINOX;Granulocyte colony-stimulating factor (G-CSF)
24 Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery Recruiting NCT01465659 Phase 1, Phase 2 temozolomide;pazopanib hydrochloride
25 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
26 Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors Recruiting NCT02259725 Phase 2 regorafenib
27 Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery Active, not recruiting NCT02101918 Phase 2
28 Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery Active, not recruiting NCT01229943 Phase 2 Everolimus;Octreotide Acetate
29 Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01824875 Phase 2 temozolomide;capecitabine
30 Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01525082 Phase 2 capecitabine;temozolomide
31 Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer Not yet recruiting NCT02820857 Phase 2 Folfiri-bevacizumab;Folfiri
32 Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery Terminated NCT02031536 Phase 2 everolimus
33 Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer Terminated NCT02273752 Phase 2 Everolimus
34 Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors Terminated NCT00084461 Phase 2 romidepsin
35 Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors Terminated NCT00466856 Phase 2 octreotide acetate
36 Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors Withdrawn NCT00227773 Phase 2 octreotide acetate;vatalanib
37 Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy Withdrawn NCT00003514 Phase 2 antineoplaston A10;antineoplaston AS2-1
38 Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors Withdrawn NCT02108782 Phase 2 dovitinib lactate
39 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
40 Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors Completed NCT01155258 Phase 1 temsirolimus;vinorelbine ditartrate
41 Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma Completed NCT01204476 Phase 1 Everolimus;Octreotide Acetate
42 Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer Completed NCT00006368 Phase 1
43 Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors Completed NCT00049023 Phase 1
44 Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum Completed NCT00005860 Phase 1 floxuridine;leucovorin calcium;oxaliplatin
45 Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer Completed NCT00005842 Phase 1 tipifarnib
46 Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors Active, not recruiting NCT00655655 Phase 1 everolimus;vatalanib
47 Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Terminated NCT00002947 Phase 1
48 Post Marketing Surveillance Study To Observe Safety And Efficacy Of Sutene Completed NCT00444795 Sunitinib malate;Sunitinib malate;sunitinib malate
49 A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. Completed NCT00428220 sunitinib
50 Clinical Evaluation of i-STAT Analyzer Recruiting NCT02897154

Search NIH Clinical Center for Pancreatic Endocrine Carcinoma

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: carcinoma, islet cell

Genetic Tests for Pancreatic Endocrine Carcinoma

Anatomical Context for Pancreatic Endocrine Carcinoma

MalaCards organs/tissues related to Pancreatic Endocrine Carcinoma:

39
Pancreas, Liver, Bone, Kidney, Endothelial

Publications for Pancreatic Endocrine Carcinoma

Articles related to Pancreatic Endocrine Carcinoma:

(show all 17)
id Title Authors Year
1
Granulomatous Insulitis as a Cause of Acute-Onset Insulin-Dependent Diabetes Mellitus in a Patient With a Pancreatic Endocrine Carcinoma. ( 27160433 )
2016
2
Palladin is a marker of liver metastasis in primary pancreatic endocrine carcinomas. ( 21868544 )
2011
3
Phase II study of first-line FOLFIRI for progressive metastatic well-differentiated pancreatic endocrine carcinoma. ( 21831734 )
2011
4
Pancreatic endocrine carcinoma protruding from the major papilla. ( 20144741 )
2010
5
A case of multiple hepatic metastases from pancreatic endocrine carcinoma. ( 18573853 )
2008
6
Multimodality management of a polyfunctional pancreatic endocrine carcinoma with markedly elevated serum vasoactive intestinal polypeptide and calcitonin levels. ( 18362846 )
2008
7
Successful pancreatectomy with en-bloc resection of the celiac artery and portal vein for pancreatic endocrine carcinoma. ( 17629086 )
2007
8
Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma. ( 16364959 )
2006
9
Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma. ( 17158766 )
2006
10
Somatostatin-producing pancreatic endocrine carcinoma presented as relapsing cholangitis -- a case report. ( 15849491 )
2005
11
Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas. ( 15920550 )
2005
12
The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option? ( 14962717 )
2004
13
Curative resection for a pancreatic endocrine carcinoma involving the portal vein. ( 15532841 )
2004
14
Dpc4 is expressed in virtually all primary and metastatic pancreatic endocrine carcinomas. ( 11964045 )
2002
15
Pancreatic endocrine carcinoma with multiple hormone production in a raccoon (Procyon lotor). ( 10213674 )
1999
16
Parathyroid hormone-like peptide in pancreatic endocrine carcinoma and adenocarcinoma associated with hypercalcemia. ( 1322859 )
1992
17
Pancreatic endocrine carcinoma with ectopic PTH-production and paraneoplastic hypercalcaemia. ( 3082066 )
1986

Variations for Pancreatic Endocrine Carcinoma

Expression for Pancreatic Endocrine Carcinoma

Search GEO for disease gene expression data for Pancreatic Endocrine Carcinoma.

Pathways for Pancreatic Endocrine Carcinoma

Pathways related to Pancreatic Endocrine Carcinoma according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 10.53 NCAM1 SYP

GO Terms for Pancreatic Endocrine Carcinoma

Cellular components related to Pancreatic Endocrine Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 neuron projection GO:0043005 8.8 SSTR2 SSTR5 SYP

Biological processes related to Pancreatic Endocrine Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.5 SST SSTR2 SSTR5
2 response to nutrient GO:0007584 9.37 SST SSTR2
3 digestion GO:0007586 9.26 SST SSTR2
4 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.16 SSTR2 SSTR5
5 cellular response to glucocorticoid stimulus GO:0071385 8.96 SSTR2 SSTR5
6 somatostatin signaling pathway GO:0038170 8.62 SSTR2 SSTR5

Molecular functions related to Pancreatic Endocrine Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 neuropeptide binding GO:0042923 8.96 SSTR2 SSTR5
2 somatostatin receptor activity GO:0004994 8.62 SSTR2 SSTR5

Sources for Pancreatic Endocrine Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....